For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

We use cookies to make our site as useful as possible.

Our Cookie Policy explains how you can opt-out of the cookies we use.

If you continue without changing your cookie settings, we'll assume you’re happy with this.

Continue Continue

United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Diagnostic & Therapeutic Solutions
    Custom solutions & partnerships

    Custom antibody development and commercial partnerships to advance your diagnostic and therapeutic discovery.

    Create custom solutions with us

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Supporting our customers and employees during the COVID-19 pandemic. Read more

Exploring the one-biomarker-per-drug paradigm in oncology

Related

  • Immuno-oncology resources
    • Immuno-oncology panels
      • Carrier-free antibodies
        • Our PD-L1 clones
          • Antibody discovery for IO diagnostics
            • PD-L1 antibody variation
              • ELISA kits for therapeutic antibodies
                • Immuno-oncology ELISA kits
                  • New Directions in Immuno-oncology: Response and Resistance conference (February 2021)

                    The one-biomarker-per-drug model is insufficient in immuno-oncology. We heard from experts in the field about the rise of combination biomarkers and the expected advances they will deliver. 

                    In collaboration with Science, we hosted a two-part webinar series on the theme of the changing landscape of diagnostic biomarkers in immuno-oncology. In the first part of this series, we heard from the following experts in the field:

                    Dr Sacha Gnjatic – Icahn School of Medicine at Mount Sinai, New York, NY

                    Professor David Rimm – Yale University School of Medicine, New Haven, CT

                    Dr Houssein Abdul Sater – NIH NCI Center for Cancer Research, Bethesda, MD


                    Overview

                    • Immunotherapy biomarkers in the age of precision medicine
                    • Identifying new immunotherapy biomarkers
                    • Emerging technologies: data sharing and multiplex platforms
                    • The challenges of multiple biomarkers
                    • Future perspectives: combination biomarkers
                    • Abcam's role in immuno-oncology research


                    Immunotherapy biomarkers in the age of precision medicine

                    ​Conventional oncology biomarkers showed efficient patient stratification based on a single biomarker test, eg estrogen receptor or HER2. However, diagnostics for immuno-oncology have proven more complex. Professor David Rimm stated that these single biomarker tests in oncology 'paved the way for how we would do biomarkers for immunohistochemistry in clinical labs. As new targets came through if they weren't molecular they stayed in the IHC realm, traditionally read by pathologists and traditionally only a single biomarker. That's why we saw the introduction of PD-L1 as a single biomarker read in a similar way as HER2 or ER, even though perhaps it's inadequate to capture the range of events that affect immunotherapy response.'

                    Compared to standard oncology diagnostics, immuno-oncology no longer considers the tumor as the only target from which biomarkers can be derived, rather the entire immune cell network can be analyzed for appropriate biomarkers. Profiling the immune network in this way is vital to identify biomarkers that can accurately predict patient responsiveness to treatment. A single biomarker, such as PD-L1 expression, is insufficient to capture disease-relevant immune signatures and the interactions between key cell types. For example, some patients exhibiting high PD-L1 expression do not respond to the therapeutic blockade of this immune checkpoint, while conversely, some patients with low PD-L1 expression do respond.​

                    Identifying new immunotherapy biomarkers

                    ​Understanding the mechanisms that underlie different immune signatures is important for the development of innovative and integrated assays for accurate patient stratification. Previously identified immunotherapy biomarkers include immune cell infiltrate, tumor mutational burden (TMB), and microsatellite instability; these can be used to predict the efficacy of therapies in different patient groups.

                    One major focus of immuno-oncology research is the delivery of new biomarkers to guide immunotherapy. Professor Sacha Gnjatic discussed the possibility of building diagnostic tests based on many levels: the host level with the examination of the gut microbiome from stool samples, the tissue level with the examination of stromal markers and the periphery with the examination of circulating biomarkers from liquid biopsies, in the pursuit of accurate diagnostic immuno-oncological biomarker panels.

                    Large-scale patient studies, big-data analysis, and bioinformatics integrations are being employed in this field to accelerate biomarker discovery, with the use of multiplex assays and combination assays to improve diagnostic tests, using these novel biomarkers.​

                    Emerging technologies: data sharing and multiplex platforms

                    The adoption of multiple RNA and protein markers into a single specific biomarker signature for patient stratification is dependent upon the ability to generate, integrate, and monitor multiple antigens in parallel, on a sufficiently large scale for effective implementation within the clinic. This is not a simple task, requiring new technologies and complex protocols.

                    The Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) is an initiative that aims to improve clinical trials in immuno-oncology through the application of new technologies and data analytics. A suite of technologies including multiplex IHC, mass cytometry, RNA sequencing, whole-exome sequencing, and serum cytokine analysis is being used across four main centers. This network will serve as a resource to support immunotherapy research and early-phase clinical trials.

                    Mass cytometry is a high-throughput protein analysis technique that involves labeling specific proteins within a sample with heavy metal–conjugated "carrier-free" antibodies. This technology currently enables the simultaneous analysis of up to 50 markers from a single cell.

                    The challenges of multiple biomarkers 

                    Challenges facing the adoption of multiple biomarkers as a signature, rather than single biomarkers, include harmonization, integration, reimbursement, and commercial viability. A lack of full concordance between different tests for the same target has been shown for the well-known biomarker PD-L1, where tests differ in their scoring criteria and interpretation. This variation may increase further when integrating multiple tests to different biomarkers, as differences in sampling, labs, equipment and conditions will all exacerbate the variations.

                    One factor that continues to hinder the adoption of multiplex testing according to Rimm is that 'when new assays come in, especially more complicated assays there has to be some need from the drug perspective.  When we started to look at 20-30 different targets at once, we saw the adoption of NGS in pathology labs. Not all labs could do it, it's a very complicated test, but it is an example of where you could see a complicated test being adopted that solves a problem, that is the need to assess multiple genes and biomarkers at one time. I think that's now happening in the IO space for proteins. We will see whether these multiplex tests come to prominence. Once there's a need for it for the specificity in predicting response to therapy and that's what we're seeing now.

                    Future perspectives: combination biomarkers

                    ​​Identifying the best combination of biomarkers that can provide an accurate prediction of tumor response requires much further research. Gnjatic told us how ‘We are still trying to figure out the biology… All these biological insights of how the mechanisms of each biomarker Is actually working, will help to refine the test and make it more relevant in terms of why it is useful in predicting response to therapy’.

                     Many different markers and combinations of markers are under investigation. Professor Houssein Abdul Sater raised the possibility of implementing unsupervised diagnsotics, with data from ‘Segmentation of tissue and spatial analyses and having all these details and putting them into an AI-based model rather than a supervised annotated approach.’ While Sater also agreed with Rimm that the future immune-ocology diagnsotics would ‘Use high-plex assays to uncover smaller assays with predictive value,…finding the key set and the right biomarkers that display maximum sensitivity and specificity being reduced to a smaller set for clinical assay.’

                    The first webinar is still available to watch. To view the next webinar in the series, “The changing landscape of diagnostic biomarkers: Revealing the future of diagnostics, from singleplex to multiplex”, click here. 

                    Abcam’s role in immuno-oncology research

                    To push the boundaries of what we can achieve for future diagnostic tests, researchers need access to a diverse range of reliable research tools and expertise. At Abcam, we have a strong immuno-oncology focus, and we are frequently developing new research tools for emerging and established immuno-oncology targets. We strive to test and validate our products in relevant healthy and diseased tissues and assay situations to ensure the best performance.

                    We're happy to help you with the tools or support you need to accelerate your research, antibody discovery, and/or companion diagnostic development.​​




                    Get resources and offers direct to your inbox Sign up
                    A-Z by research area
                    • Cancer
                    • Cardiovascular
                    • Cell biology
                    • Developmental biology
                    • Epigenetics & Nuclear signaling
                    • Immunology
                    • Metabolism
                    • Microbiology
                    • Neuroscience
                    • Signal transduction
                    • Stem cells
                    A-Z by product type
                    • Primary antibodies
                    • Secondary antibodies
                    • Biochemicals
                    • Isotype controls
                    • Flow cytometry multi-color selector
                    • Kits
                    • Loading controls
                    • Lysates
                    • Peptides
                    • Proteins
                    • Slides
                    • Tags and cell markers
                    • Tools & Reagents
                    Help & support
                    • Support
                    • Make an Inquiry
                    • Protocols & troubleshooting
                    • Placing an order
                    • RabMAb products
                    • Biochemical product FAQs
                    • Training
                    • Browse by Target
                    Company
                    • Corporate site
                    • Investor relations
                    • Company news
                    • Careers
                    • About us
                    • Blog
                    Events
                    • Tradeshows
                    • Conferences
                    International websites
                    • abcam.cn
                    • abcam.co.jp

                    Join with us

                    • LinkedIn
                    • facebook
                    • Twitter
                    • YouTube
                    • Terms of sale
                    • Website terms of use
                    • Cookie policy
                    • Privacy policy
                    • Legal
                    • Modern slavery statement
                    © 1998-2021 Abcam plc. All rights reserved.